Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech AG has reached its target enrollment in its phase III trial of its lead anticancer candidate satraplatin in the treatment of patients with hormone-refractory prostate cancer.
Subscribe to our email newsletter
The trial is a multicenter, multinational trial that is assessing the safety and efficacy of the drug in combination with prednisone as second-line chemotherapy in patients with the condition, which is the most common cancer among men in the US and Europe.
More than 200 clinical sites in fifteen countries have enrolled 912 patients to the trial. A number of additional patients are in screening, and the company says that it will allow those patients to complete the process and either be randomized into the trial or disqualified, in accordance with the trial protocol.
“The rapid accrual rate of the SPARC trial supports the need for effective second-line chemotherapy treatments for hormone-refractory prostate cancer patients,” said Dr Bernd Seizinger, CEO. “We are thus committed to completing the study and moving forward in the registration process as expeditiously as possible.”